CD274 and neoplasm: ORR objective response rate, AE adverse event, DLT dose limited toxicity, LEN Lenvatinib, PEM Pembrolizumab, MTD maximum tolerance dose, DOR duration of response, dMMR mismatch repair deficient, PFS progression-free survival, OS overall survival, CR complete response, PD-L1 programmed cell death ligand 1, TMB tumor mutation burden